Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino · Clinical Investigation · 2011
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2011
Abstract
The introduction of rituximab in combination with chemotherapy has substantially changed the outcome of patients with diffuse large B-cell lymphoma. This update will discuss the factors that improved our predictive capacity in these lymphomas and the results obtained by large clinical trials in first-line and salvage therapy. As far as first-line therapy is concerned, mature data are available for low-risk patients younger than 60 and for elderly patients; for patients older than 60 with unfavorable risk factors, conclusive data are still pending.
Despite major advances in the first-line therapy, approximately half of the patients with diffuse large B-cell lymphoma experience treatment failure or refractoriness to first-line therapy. The standard therapy in these patients is high-dose chemotherapy followed by peripheral stem cell transplantation as hematologic rescue. Prior rituximab, as part of first-line therapy, does adversely influence the outcome of salvage therapy. New molecules and antibodies are being investigated in Phase I/II studies in patients who have relapsed or exhibit primary refractoriness and in those not eligible for peripheral stem cell transplantation. The new perspectives with these agents will be discussed.
Open the resolved locator · 10.4155/cli.11.70
Metadata licence: OpenAlex metadata (CC0)